A placebo-controlled efficacy study of the intravesical immunomodulators TMX-101 and TMX-202 in an orthotopic bladder cancer rat model.

Johannes Falke,Christina A Hulsbergen-van de Kaa,Roberto Maj,Egbert Oosterwijk,J Alfred Witjes

World journal of urology（2018）

引用 5|浏览20

暂无评分

摘要

TMX-101 and TMX-202 are TLR-7 agonists with antitumor activity. Treatment with TMX-101 and TMX-202 resulted in less tumor-bearing rats compared to vehicle or saline control groups, although not statistically significant. In this aggressive bladder cancer model, a lower number of tumor-positive rats after treatment with TLR-7 agonists indicates activity for the treatment of non-muscle invasive bladder cancer.

查看译文

关键词

Toll-like receptor,Non-muscle invasive bladder cancer,Imiquimod,TMX,Immunomodulator,TLR-7

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要